Dear reader,
The world is changing fast.
As an investor you know change equals opportunity…the bigger the change, the bigger the opportunity.
The next few years are going to be either the most interesting, exciting, and lucrative years for you or you’re going to be left behind.
Dynamic Wealth Research has targeted three of the fastest growing and most disruptive changes poised to make early investors fortunes.
In the the following report you will learn about all three of these changes, the hyper-growth opportunities they’re creating, and specific moves you can do now to ensure you’re on the right side of the future.
You’re going to get the early edge on:
- The one company combining artificial intelligence, automation, and robotics all in one
- The REAL reason the NFL ratings (and all TV ratings) are declining and the company seeing “Netflix-style” growth as a result
- An early look at how to ride the exploding growth of the still-unknown medicinal psychedelics sector
Read on to ensure you’re on the exciting side of it all.
The first potential hyper growth stock for 2021 is
Mind Cure Health Inc. (CSE: MCUR OTCQB: MCURF).
Mind Cure is a rapidly rising developer of the most innovative and high-potential therapeutics for mental healthcare ever discovered.
The company is bringing together the power of innovation, technology, and biotech to develop therapies for some of the most vexing mental healthcare problems like anxiety, PTSD, addiction, and many more.
And since Mind Cure is still in the comparatively early stages of its growth trajectory, his upstart company is valued at about 1/30th of some of its peers.
There’s a lot of potential room to move up here.
We’re going to delve into the details of what Mind Cure is working on (Note: Fortune magazine says it “may transform mental health care
2”).
But here’s the real key to it all.
The puzzle only a few investors have put all the pieces together on.
And which has already proven to send shares of companies like Mind Cure soaring more than 1000%.
It is the
catalyst to unlock all this value.
And it is coming in as little as a few weeks according to a report by CNBC.
Here’s the set up of how it all happened the first time and why Mind Cure presents a way to get in on it all again.
Let me take you back to September of 2020.
That was the month when a biotech company named Compass Pathways (CMPS) completed its Initial Public Offering (IPO).
On the surface, Compass wasn’t too much different than many other biotech companies.
It had a drug therapeutic that the company has advanced to Stage 2 of the three stage FDA clinical trial process.
It had raised a good amount of money. It raised $80 million April of 2020 and then it raised an additional $107 million when it IPO’d.
But Compass is not your average biotech company.
Compass is actually a biotech and life sciences company that is using psychedelic drugs to treat chronic mental healthcare conditions.
It may sound a bit crazy at first, but psychedelics have enormous potential to finally deliver effective treatments for mental healthcare.
It’s not just Dynamic Wealth Research that sees this either.
Some of the world’s most foresightful investors are getting behind psychedelics too.
For example, Peter Thiel, the billionaire who made the first investment into Facebook (FB), has bet big on psychedelics.
In fact, Thiel and many other top Silicon Valley investors have bet big on the entire psychedelics biotech sector.
Compass Therapeutics was one of the first high-profile psychedelics companies they backed to hit the public markets.
And when Compass shares hit the markets, they went gangbusters.
They jumped 71% on the first day of trading.
They went on to climb a total of 262% over the next three months.
That’s a big return. Seriously.
But the thing is, that big run-up was just part of a much bigger trend that created a far more lucrative opportunity.
Going Big By Going Small
You see, Compass is just one of the most forward-looking biotech companies actively researching psychedelic-based therapeutics in the world.
Our biotech pick for 2021, Mind Cure Health (CSE: MCUR OTCQB: MCURF), is another one that is doing research on psychedelics.
There are quite a few more of them too.
And some of them absolutely soared after the ultra-successful Compass Pathways IPO put psychedelics on the proverbial map.
For example, Mind Medicine has quickly emerged as one of the early leaders in the psychedelics biotech space.
Its shares absolutely soared in 2020.
They rose a total of 1332% from lows set last summer.
MMED CHART 1
If you look closely, you’ll see Mind Medicine’s shares started to make their first move in September of 2020.
That’s the same time Compass Pathways completed its IPO.
The big IPO was the catalyst for the small, upstart psychedelics biotech companies.
It’s not a coincidence.
Numiness Wellness is another example.
Its shares have soared as much as 576% since bottoming out last summer.
NUMI CHART 2
Again, the bottom for Numinus came shortly before the Compass Pathways IPO put the psychedelics sector on the map.
These were huge moves in a short amount of time.
Fortunes were made.
And best of all, the same set up is coming together all over again.
The Next Major Psychedelic IPO Is Approaching Fast
ATAI Life Science is a company that has quite a few similarities to Compass Pathways.
ATAI is focused on developing psychedelic-based therapies for mental health disorders.
It is a rapidly growing company. In the two years since its founding, it has built offices in Berlin, New York, and San Diego and has partnered with 10 drug development companies.
The has earned the financial backing of Peter Thiel, the same early investor who backed Facebook and Compass Pathways.
ATAI has also attracted other big money investors when it raised $125 million in additional capital in November 2020.
It is very similar in many ways.
But here is the key.
According to a CNBC report from January 15, 2021, ATAI is set to go public in as little as a few weeks or months.
CNBC stated, “The plan is to take ATAI public in the next few months at a valuation of between $1 and $2 billion, according to an industry source that asked to remain anonymous due to the nature of the discussions.3”
That’s exactly what we saw last September.
A sizable psychedelics company, backed by prominent investors, completing a major IPO.
It launched many smaller psychedelic biotech companies.
And this is where Mind Cure Health (CSE: MCUR OTCQB: MCURF) comes into play.
Upstart Psychedelic Ramping Up Growth
Mind Cure is a true ground-floor opportunity in one of the most exciting biotech and health care innovations to come along in years.
This small company sits at the forefront of one of the most exciting fields in mental health care.
Our colleagues at Psychedelic Stock Watch describe Mind Cure as:
Mind Cure is a mental health and wellness company focused on identifying, developing and commercializing products that enhance mental health and wellness, ease suffering and increase productivity in the midst of global mental health crisis.
The company is focusing on the five largest aspects of the psychedelic-derived research market.
Mind Cure is in prime position in the psychedelics sector.
And the timing for it couldn’t be better with CNBC stating the ATAI IPO is coming in the next few months.
Mind Cure is in position to do exceptionally well if the ATAI IPO sparks another run in psychedelic stocks too.
At the start of 2021, Mind Cure had a total market cap of about $25 million.
That’s as little as 1/30th of companies like Mind Medicine, Compass Therapeutics, and what ATAI will likely see when it comes public.
Will history repeat?
If it does, psychedelic stocks are going to catch fire and investors moving in now will be sitting on huge gains by then.
Read our Full Report on MInd Cure (OTC: MCURF | CSE: MCUR) Here!
Hyper Growth Stock #2:
Rise Of The Machines: Artificial Intelligence Is The Next Big Thing In Tech
Mark Cuban predicted artificial intelligence will create the world’s “first trillionaire.”
It’s going to happen sooner than later too.
Naveen Rao, head of Intel’s Artificial Intelligence Products Group, said, “I think the next five or six years [in artificial intelligence] are going to be really, really fast moving.”
Even five years may be a bit of an understatement because researchers at International Data Corporation estimate the demand for artificial intelligence-based applications to rise from $12 billion in 2017 to more $47 billion by 2020.
That’s a near quadrupling of the industry in just three years and it’s just the kind of hyper-growth which creates massive gains for early investors too.
The time to move into artificial Intelligence is right now too.
Because artificial intelligence is not
going to change the way you live, work, and play.
It already has changed it all and the changes, effects, and gains for investors will only grow exponentially from here.
After all, a recent survey from Gallup found 86% of U.S. consumers used some form of artificial intelligence.
Google Maps and Waze use artificial to incorporate real-time traffic data and distance to determine the route to where you want to go.
Netflix uses it to determine movies and shows you would would probably enjoy.
Pandora and Spotify use it to determine new music you may like.
Google and Facebook use your past Internet history and relationships to determine what content may most interest you and ads for products your most likely to be interest in.
Artificial intelligence is everywhere and it’s only going to get faster and better as it ramps up from here.
Now, here’s the thing about it all though.
Artificial intelligence is complicated and it requires armies of coders and technicians to develop and apply.
It also requires massive amounts of processing power.
As a result, the big winners in the artificial intelligence will be those companies with the size and scale ton harness it in as broad and complex solutions as possible.
In artificial intelligence, bigger is better.
So if you want to ride the artificial intelligence boom, you’ve got to go big.
That’s why
Microsoft (MSFT) is an early leader in artificial intelligence and will be a leader in artificial intelligence of the future.
Few companies have the resources, manpower, and ready access to hundreds of millions of customers devices around the world.
The early successes from Microsoft with its customers are already reach into the billions of dollars of value created.
Manufacturing, finance, transportation, and healthcare are ripe for the disruptive force of artificial intelligence. Microsoft will play an essential role in all of that.
Hyper Growth Stock #3:
Death of TV and Hollywood, Rise of Gaming and eSports
TV, as you know it, is going the way of the CD and music store at the mall.
Traditional entertainment industries are in irreversible decline.
A new generation of entertainment and media companies are going to take their place.
The rise of Netflix and its subscriber base of 118 million are just the start of a revolution transforming the entertainment world.
There are fortunes to be had from it all too.
Netflix, for example, was a $20 stock five years ago. This year it blew past $300 a share.
However, it’s got a problem.
It’s just a screen and a viewer.
There’s no variability or interaction. There’s no loyalty. There’s no devotion from a growing army of fans.
That’s where
Activision Blizzard (ATVI) is transforming one of the fastest-growing entertainment sectors in the world.
Activision is leading a true entertainment industry revolution and it’s taking an ever-increasing share of consumers’ entertainment time and dollars.
Let me show you about two of the world’s biggest sporting events.
The Super Bowl is the centerpiece of the NFL’s cashflow machine. It attracted 111 million viewers and had advertisers cough up $5 million for a 30 second spot.
It’s nothing compared to what’s happening in Esports though.
Esports are live video game competitions and their massive and getting even bigger.
The most recent major Esporting event was the League of Legends Mid-Season Invitational.
It attracted 360 million unique viewers.
That’s three times bigger than the Super Bowl and, with a global audience, it’s still growing too.
Video games are becoming more advanced, engaging, and, most importantly, attracting more players for longer periods of time than ever before.
Activision is one of the largest providers of these high-quality video games in the world.
Activision’s most successful game is the “Call of Duty” series.
It’s a first-person shooter franchise which has built a maniacal following over the years.
When Call of Duty: Black Ops II was released it booked sales of $550 million in its first weekend.
No movie has ever even come close to that.
It also has leading game franchises which attract hours and hours of players’ time including World of Warcraft, Candy Crush Saga, and Destiny.
Activision also owns Major League Gaming which is a competitive Esports league based on Activision’s leading games.
Gaming is getting more interactive, building more intense followers, and become more profitable all along the way.
Activision has multiple brands and franchises within the gaming industry which will be increasingly valuable in the years ahead.
Hyper-Growth Action Review
In the end, no one can deny the world is changing at an ever-increasing rate.
Change can mean big profits for investors getting in on the biggest changes early.
These three sectors -- medicinal psychedelics, artificial intelligence, advanced gaming -- are all seeing massive changes are and we’re just starting to see their impact in the world.
Historically, when you just start to see these changes is the the best time time to buy.
And it’s why in a few years you’ll be kicking yourself for not jumping on them when you had the chance.
Some of the best, most direct, and highest-potential ways to jump on them are with
Mind Cure (OTC: MCURF | CSE: MCUR), Microsoft (MSFT), and Activision Blizzard (ATVI)
Best regards,
Dynamic Wealth Research
MMED CHART 1 From $0.338 per share on September 14, 2020, to $4.84 per share on December 11, 2020 per stockwatch.com – a gain of 1332% per online percentage calculator at: https://percentagecalculator.net/.
NUMI CHART 2 From $0.33 a share on October 15, 2020, to $2.23 a share on December 14, 2020, per stockwatch.com – a gain of 576% per online percentage calculator at: https://percentagecalculator.net/.
----------------------------------------
Please see full disclaimers at www.DynamicWealthResearch.com applicable to all content provided by DWR , wherever published or republished: https://dynamicwealthresearch.com/about/disclaimer
Disclaimer: This release/advertorial is a commercial advertisement and is for general information purposes only. This release/advertorial does not constitute an offer or solicitation to buy or sell any securities or individualized investment advice. This is a native advertisement, meaning it is an informational paid marketing piece. Dynamicwealthresearch.com (DWR) makes no recommendation that the securities of the issuers profiled or discussed on this website should be purchased, sold or held by viewers, whether or not viewers learn of the profiled issuers through our website or otherwise. Please review all investment decisions with a licensed investment advisor.
DWR receives media support and payments from the issuer or third-party companies that have contracted with the issuer ranging from approximately $25,000 to $150,000 to publish and/or distribute advertisements on behalf of the issuer. The issuer and/or third-party companies that have contracted with the issuer have not promised exclusivity to DWR and may hire additional publishers or advertisers on behalf of the issuer. DWR retains any excess sums after expenses as its compensation. DWR may be paid for services using cash, options, restricted shares, free-trading shares, or shares of other unrelated issuers, and thus DWR and its owners, operators and affiliates may benefit from any increase in the share prices of the profiled issuers.
DWR and/or its owners, operators and affiliates make no representations about their short-term or long-term investment horizons and may be selling shares of stock at the same time the profile (or other information) is being disseminated to potential investors; DWR is under no obligation to, and will not, advise any party when it or its affiliates decide to buy or sell shares. Investors must make all investment decisions based on their own judgment of the market and the particular securities.
This release/advertorial contains forward-looking statements that involve risks and uncertainties. This release/advertorial contains or incorporates by reference forward-looking statements, including certain information with respect to plans and strategies of the featured issuer. As such, any statements contained herein or incorporated herein by reference that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the foregoing, the words “believe(s),” “anticipate(s),” “plan(s),” “expect(s),” “project(s),” “will,” “make,” “told,” “could,” “might,” and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual events or actual results of the issuer to differ materially from these indicated by such forward-looking statements. Certain statements contained herein are forward-looking statements as defined in Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Such statements include, without limitation, statements regarding business, financing, business trends, future operating revenues and expenses. There can be no assurance that such expectations will prove to be correct. Investors are cautioned that any forward-looking statements made by the issuer or DWR or contained in this release/advertorial are not guarantees of future performance, and that the issuer’s actual results may differ materially from those set forth in the forward-looking statements. We undertake no obligation to update any statements made herein. Differences in results can be caused by various factors including, but not limited to, the issuer’s ability to be able to successfully complete planned funding agreements, to successfully market its products in competitive industries or to effectively implement its business plan or strategies. To reiterate, information presented in this release/advertorial contains “forward-looking statements.” Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performance are not statements of historical fact and may be “forward-looking statements.” Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. More information on the issuer that is the subject of this release/advertorial may be found at http://www.sec.gov where readers can review all public filings submitted by the issuer. DWR is not a certified financial analyst, investment advisor, broker/dealer, or licensed in the securities industry in any manner. The information in this advertorial is subjective opinion and may not be complete, accurate or current and was paid for by the issuer, creating a potential conflict of interest.
